Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy males or females according to the investigator's assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG and clinical laboratory tests.~2. Age 18 to 50 years (inclusive)~3. BMI 18.5 to 29.9 kg/m2 (inclusive)~4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation.~Exclusion criteria:~1. Any finding in the medical examination (Including blood pressure \[BP\], pulse rate \[PR\], or electrocardiogram \[ECG\]) deviating from normal and judged clinically relevant by the investigator.~2. Any evidence of a concomitant disease judged clinically relevant by the investigator.~3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.~4. Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug(s)~5. Diseases of the central nervous system (such as epilepsy), other neurological disorders or psychiatric disorders.~6. History of relevant orthostatic hypotension, fainting spells, or blackouts.~7. Chronic or relevant acute infections~8. History of relevant allergy/hypersensitivity (including allergy to the trial medication or it's excipients)~9. Intake of drugs with a long half-life (\>24 hours) within 30 days or less than 10 half-lives of the respective drug prior to administration of trial medication.~10. Within 14 days prior to the administration of trial medication, use of drugs that might reasonably influence the results of the trial, based on current knowledge~11. Participation in another trial with investigational drug administration within 60 days prior to administration of trial medication.~12. Smoker (has used tobacco or nicotine-containing products within 6 months prior to administration of trial medication)~13. Inability to refrain from smoking on specified trial days~14. Alcohol abuse (consumption of more than 20g/day in females and 30g/day in males or \> 7 alcohol-containing drinks per week)~15. Drug abuse or positive drug screen~16. Blood donation (more than 100 ml wihtin 30 days prior to administration of trial medication or intended during the trial)~17. Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial~18. Inability to comply with dietary regimen of trial site~19. Subject is assessed by the investigator as unsuitable for inclusion, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study.~    For female subjects:~20. Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after study completion.~21. No adequate contraception during the study and until 1 month after study completion, i.e. not any of the following: implants, injectables, combined oral contraceptives, IUD (intrauterine device), sexual abstinence for at least 1 month prior to enrolment, vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy). Females, who do not have a vasectomised partner, are not sexually abstinent, surgically sterile, or post menopausal will be asked to use an additional barrier method (e.g. condom, diaphragm with spermicide). Post-menopausal is defined as at least 1 year of spontaneous amenorrhea and deemed post menopausal by a physician based on screening clinical laboratory tests (follicle stimulating hormone and luteinizing hormone).~22. Lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Fixed Dose Combination (FDC) (Type: EXPERIMENTAL): 12.5 mg Empagliflozin / 500mg metformin fixed dose combination
- Separate tablets (Type: ACTIVE_COMPARATOR): Empagliflozin and Metformin tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete